Eli Lilly has announced promising results for its oral GLP-1 drug, orforglipron, which could rival injectable medications like Ozempic for managing weight and blood sugar levels. The Phase 3 trial demonstrated significant efficacy and a safety profile similar to existing GLP-1 treatments. This advancement may impact competitors such as Novo Nordisk.
— new from Axios